|Target||Interferon α/β receptor|
|Chemical and physical data|
|Molar mass||145.12 kg/mol g·mol−1|
Anifrolumab is a monoclonal antibody designed for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
Clinical trial results
Anifrolumab failed to meet its endpoint of significant reduction in disease as assessed by the SLE Responder Index 4 instrument in the TULIP 1 phase III trial. This multi-center, double-blind, placebo-controlled study followed adults with moderate to severe SLE over the course of one year. Preliminary results were announced on 31 August 2018.
The most common adverse effect was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
- "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
- "Anifrolumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
- "Anifrolumab". AdisInsight. Retrieved 31 July 2017.
- "Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus". www.astrazeneca.com. Retrieved 2019-02-05.
- H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|